Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS.

Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Review.

PMID:
18619560
[PubMed - indexed for MEDLINE]
2.

CYP17 inhibitors for prostate cancer therapy.

Vasaitis TS, Bruno RD, Njar VC.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):23-31. doi: 10.1016/j.jsbmb.2010.11.005. Epub 2010 Nov 17. Review.

PMID:
21092758
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

PMID:
22291466
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Zhu H, Garcia JA.

Curr Oncol Rep. 2013 Apr;15(2):105-12. doi: 10.1007/s11912-013-0300-1. Review.

PMID:
23371447
[PubMed - indexed for MEDLINE]
5.

CYP17 inhibition as a hormonal strategy for prostate cancer.

Reid AH, Attard G, Barrie E, de Bono JS.

Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237. Review.

PMID:
18985049
[PubMed - indexed for MEDLINE]
6.

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM.

Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230.

PMID:
18723482
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
[PubMed - indexed for MEDLINE]
8.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558
[PubMed - indexed for MEDLINE]
9.

Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.

Njar VC, Brodie AM.

Curr Pharm Des. 1999 Mar;5(3):163-80. Review.

PMID:
10066888
[PubMed - indexed for MEDLINE]
10.

Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.

Bedoya DJ, Mitsiades N.

Expert Rev Anticancer Ther. 2012 Jan;12(1):1-3. doi: 10.1586/era.11.196. No abstract available.

PMID:
22149426
[PubMed - indexed for MEDLINE]
11.

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Attard G, Richards J, de Bono JS.

Clin Cancer Res. 2011 Apr 1;17(7):1649-57. doi: 10.1158/1078-0432.CCR-10-0567. Epub 2011 Mar 3. Review.

PMID:
21372223
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.

Gianti E, Zauhar RJ.

J Chem Inf Model. 2012 Oct 22;52(10):2670-83. doi: 10.1021/ci3002342. Epub 2012 Oct 1.

PMID:
22924551
[PubMed - indexed for MEDLINE]
13.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Yin L, Hu Q.

Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Review.

PMID:
24276076
[PubMed - indexed for MEDLINE]
14.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
[PubMed - indexed for MEDLINE]
15.

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.

Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Epub 2013 Jun 10. Review.

PMID:
23752196
[PubMed - indexed for MEDLINE]
16.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.

J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.

PMID:
20159824
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
[PubMed - indexed for MEDLINE]
18.

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.

Nandha R.

J Postgrad Med. 2012 Jul-Sep;58(3):203-6. Review.

PMID:
23023354
[PubMed - indexed for MEDLINE]
Free Article
19.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25.

PMID:
21868758
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk